Merus to Participate in Upcoming Investor Conferences
31 Enero 2024 - 7:00AM
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced that Bill Lundberg,
M.D., President, Chief Executive Officer of Merus, will participate
in a fireside chat at the following investor conferences:
- Guggenheim 6th Annual Biotechnology
Conference: Wednesday, February 7, 2024 at 2:30 p.m. ET
- Citi’s 2024 Oncology Leadership
Summit: Thursday, February 22, 2024 at 9:00 a.m. ET
The webcasts of the presentations will be contemporaneously
available on the Investors page of the Company's website. Archived
presentations will also be available there for a limited time after
the event.
About MerusMerus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics,
referred to as Multiclonics®. Multiclonics® are manufactured
using industry standard processes and have been observed in
preclinical and clinical studies to have several of the same
features of conventional human monoclonal antibodies, such as long
half-life and low immunogenicity. For additional information,
please visit Merus’ website and twitter.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Merus NV (NASDAQ:MRUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024